RxDoctor Payments Data

Humberto Porrata, MD

Interventional Pain Medicine · Wellington, FLNPI 1114920758

Payments from drug & device makers

$3,024in general payments, 2019–2025

Across 153 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$685
  • Abbott$519
  • Nevro Corp.$414
  • Novo Nordisk$322
  • Amgen$270
  • Si-bone, Inc.$154
  • plus $660 from 21 others

What the payments were for

  • Food & beverage$3,024100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,024 in reported general payments places this provider in the 35th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$429,933
Medicare patients
337
Services billed
6,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate133$85,821
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,873$63,216
OxycontinOxycodone Hcl38$39,055
MovantikNaloxegol Oxalate47$20,349
Fentanyl154$16,992
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen805$16,253
LinzessLinaclotide25$13,739
Oxycodone Hcl351$8,043
Buprenorphine25$5,561
Tramadol Hcl451$3,452
Morphine Sulfate ErMorphine Sulfate109$3,289
Lidocaine45$3,167
Gabapentin269$2,823
Diclofenac Sodium83$2,267
Cyclobenzaprine Hcl211$2,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$685$85,821133 claims
Redhill Biopharma Inc.Movantik$23$20,34947 claims
AbbVieLinzess$27$13,73925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →